摘要
目的分析非瓣膜性心房颤动(房颤)患者使用达比加群酯联合阿司匹林进行治疗的临床疗效及安全性。方法120例非瓣膜性房颤患者,根据随机数字表法分为对照组和实验组,各60例。对照组患者采用常规抗凝治疗,实验组患者采用达比加群酯联合阿司匹林治疗。对比两组患者的治疗效果及不良反应发生情况。结果实验组患者的治疗总有效率为93.33%(56/60),高于对照组的73.33%(44/60),差异具有统计学意义(P<0.05)。实验组患者的不良反应发生率为23.33%(14/60),低于对照组的51.67%(31/60),差异具有统计学意义(P<0.05)。结论应用达比加群酯联合阿司匹林治疗非瓣膜性房颤可取得显著的疗效且安全性高,值得在临床上推广和应用。
Objective To analyze the clinical efficacy and safety of dabigatran etexilate combined with aspirin in the treatment of non-valvular atrial fibrillation.Methods A total of 120 patients with nonvalvular atrial fibrillation were divided into control group and experimental group according to random numerical table,with 60 cases in each group.The control group was treated with conventional anticoagulant therapy,and the experimental group was treated with dabigatran etexilate combined with aspirin.The therapeutic effect and occurrence of adverse reactions of the two groups were compared.Results The total effective rate of treatment of the experimental group was 93.33%(56/60),which was higher than 73.33%(44/60)of the control group,and the difference was statistically significant(P<0.05).The incidence of adverse reactions of the experimental group was 23.33%(14/60),which was lower than 51.67%(31/60)of the control group,and the difference was statistically sigificant(P<0.05).Conclusion Dabigatran etexilate combined with aspirin has significant efficacy on nonvalvular atrial fibrillation with high safety,which is worthy of clinical promotion and application.
作者
董赫
DONG He(Dalian Central Hospital,Dalian 116003,China)
出处
《中国现代药物应用》
2021年第2期114-116,共3页
Chinese Journal of Modern Drug Application
